ADVOCACY

FDA Rule Resources for Laboratories

AMP maintains the following list of resources as a service to our membership and the molecular laboratory community. Check back often - this page will update when new information becomes available.

FDA Rule compliance stage-specific resources are sorted by stage below; resources may appear in multiple sections.  AMP does NOT certify that the information contained within the linked external resource pages is complete, accurate, and/or free of commercial bias. By clicking on an external resource link below, you will leave the AMP website. If you identify an additional resource for inclusion or find a broken link, please contact us. *Member-only resource $May require purchase

If you need specific guidance or assistance with compliance with the FDA medical device regulations, AMP encourages you to seek out licensed counsel and/or certified regulatory affairs professionals.


Quick links to sections below 

AMP Resources         Code of Federal Regulations     Regulatory Education Resources (non-FDA)

FDA Center for Devices and Radiological Health (CDRH)     

FDA Final Rule Informational / Impact of Final Rule Resources

STAGE 1: Medical Device Reporting (MDR), Correction & Removal Reporting, & Complaint File

STAGE 2: Registration & Listing, Labeling, Investigational Device Exemption (IDE)

STAGE 3: Quality System Requirements (QSR), Design Controls, Purchasing Controls, Acceptance Activities, Corrective & Preventative Actions, Records Requirements

STAGE 4: Premarket Approval (PMA) Required for High-risk In Vitro Diagnostics (IVDs)

New York State DOH LDT 3rd Party Review Program         

FDA CDER Medical Device Digital Health

Molecular Testing Validation Resources


AMP Resources 

AMP Members, use the CHAMP community when you have questions for your AMP colleagues Visit CHAMP

AMP's work on LDTs

AMP v. FDA: A discussion on the lawsuit filing & other related materials

 

Q & A WITH THE FDA  

AMP will collect your professional questions, send them to the FDA, and anonymously post the answers received below.

Site-specific questions? Contact LDTFinalRule@fda.hhs.gov, licensed counsel, and/or certified regulatory affairs professionals.

SUBMIT POLICY / REGULATORY QUESTIONS

SUBMIT LABORATORY PRACTICE / COMPLIANCE QUESTIONS 

Questions sent to FDA: 

  • Policy / regulatory - TBD
  • Laboratory practice / compliance – TBD

Replies from the FDA: 

  • Policy / regulatory - TBD
  • Laboratory practice / compliance – TBD

 

WEBINARS 

5/9/2024: Final Rule: FDA Rule Medical Device; Laboratory Developed Tests Slides 

9/16/2024: A Discussion on the Recent AMP Lawsuit Filing Slides 

PRACTICE GUIDELINES


Code of Federal Regulations 

Federal Register - Medical Devices; Laboratory Developed Tests (FDA Final Rule, 5/6/2024) 

Code of Federal Regulations (CFR) Title 21 Part 803 -- MEDICAL DEVICE REPORTING key terms are defined

Final Rule on Electronic Medical Device Reporting (eMDR) 

Proposed Rule: Microbiology Devices; Reclassification of Antigen, Antibody, and Nucleic Acid-Based Hepatitis B Virus Assay Devices (9/25/2024) 


Regulatory Education Resources (non-FDA) 

DOCUMENTS (see stages below for additional resources) 

Navigating FDA’s LDT Final Rule: Key Terminology Every Clinical Lab Should Know (Today’s Clinical Lab) 

WEBINARS (see stages below for additional resources) 

Regulatory Education for Industry (REdI) Annual Conference 2024 (5/29-30/2024) 

Professional Association Sponsored

Assorted sponsors


FDA Center for Devices and Radiological Health (CDRH) 

Wherever possible, FDA guidance is sorted on this webpage by the applicable FDA Rule compliance stage

FDA WEBINARS / CDRH LEARN MODULES

FDA FINAL RULE: Federal Register - Medical Devices; Laboratory Developed Tests (5/6/2024)

Laboratory Developed Tests (LDTs)

Medical Devices

Medical Device User Fees

Medical Device Reporting (MDR): How to Report Medical Device Problems

CDRHNews - News and Updates

FDA CDRH Events (including webinars)

Total Product Life Cycle Advisory Program (TAP) 

 

FDA WEBINARS  

CDRH Learn 

5/14/2024: Final Rule: Medical Devices; Laboratory Developed Tests

6/5/2024: Draft Guidances on Enforcement Policy for Certain In Vitro Diagnostic Devices for Immediate Public Health Response in the Absence of a Declaration Under Section 564 (applicable to LDTs) and Consideration of Enforcement Policies for Tests During a Section 564 Declared Emergency (applicable to IVDs)

7/16/2024: In Vitro Diagnostic Product (IVD): Classification

10/24/2024: FDA’s Total Product Lifecycle Approach to In Vitro Diagnostic Products

 

FDA PUBLISHED GUIDANCE DOCUMENTS 

Laboratory Developed Tests: Frequently Asked Questions 

Laboratory Developed Tests: Small Entity Compliance Guide 

Enforcement Policy for Certain In Vitro Diagnostic Devices for Immediate Public Health Response in the Absence of a Declaration under Section 564 - Draft Guidance for Laboratory Manufacturers and Food and Drug Administration Staff 

 

FDA MEDICAL DEVICE DATABASES 

Establishment Registration & Device Listing 

Recognized Consensus Standards: Medical Devices 

Search for FDA Guidance Documents 

Clinical Laboratory Improvement Amendments (CLIA) 

Device Classification 

510(k) Premarket Notification 

Premarket Approval (PMA) 

Device Classification Under Section 513(f)(2)(De Novo) 

Manufacturer and User Facility Device Experience (MAUDE) Database 

CDRH Export Certificate Validation (CECV) 

CDRH FOIA Electronic Reading Room 

CFR - Code of Federal Regulations Title 21 

Humanitarian Device Exemption (HDE) 

Medical Product Safety Network (MedSun) Reports 

Post-Approval Studies (PAS)  

522 Postmarket Surveillance Studies  

Medical Device Recalls 

Total Product Life Cycle (TPLC) 


FDA Final Rule Informational / Impact of Final Rule Resources 

FDA MEDICAL DEVICE WEBSITES AND ONLINE RESOURCES 

CDRHNew - News and Updates 

FDA CDRH Events (including webinars)  

Total Product Life Cycle Advisory Program (TAP) 

Coronavirus (COVID-19) and Medical Devices 

Definitions and General Oversight: Laboratory Developed Tests FAQs 

Specific Test Categories or Technologies: Laboratory Developed Tests FAQs 

Phaseout Policy and Enforcement Discretion Policies: Laboratory Developed Tests FAQs 

Premarket Review: Laboratory Developed Tests FAQs 

Resources and Interactions with FDA: Laboratory Developed Tests FAQs 

Labeling: Laboratory Developed Tests FAQs 

Medical Device Reporting, Complaints, and Corrections & Removals Reporting: Laboratory Developed Tests FAQs 

Investigational Use: Laboratory Developed Tests FAQs 

 

FDA PUBLISHED GUIDANCE 

8/22/2024 Draft Guidance: Predetermined Change Control Plans for Medical Devices 

Proposed Rule: Microbiology Devices; Reclassification of Antigen, Antibody, and Nucleic Acid-Based Hepatitis B Virus Assay Devices (9/25/2024) 

 

FDA WEBINARS / CDRH LEARN MODULES  

5/14/24: Laboratory Developed Tests; Medical Devices: Final Rule Slides Transcript 

An Introduction to FDA's Regulation of Medical Devices  Slides Transcript 

How is CDRH Structured? Slides Transcript 

Is My Product a Medical Device? Slides Transcript 

An Introduction to the Medical Device User Fee Program: MDUFA V Slides Transcript 

Standards 

Cross-Cutting Premarket Policy 

510(k) Third Party Review Program (intended for Third Party Review Programs) 

De Novo 

 

DOCUMENT RESOURCES 

Navigating FDA’s LDT Final Rule: Key Terminology Every Clinical Lab Should Know (Today’s Clinical Lab) 

Summary and analysis of Food and Drug Omnibus Reform Act of 2022 (Hyman, Phelps & McNamara, P.C.) 

 

ONLINE RESOURCES Coming soon!

 

ADDITIONAL WEBINARS 

Professional Association sponsored 

Assorted sponsors 


STAGE 1: Medical Device Reporting (MDR), Correction & Removal Reporting, & Complaint File

 

REPORTER WHAT TO REPORT REPORT
FORM #
TO WHOM WHEN
Manufacturers 30 day reports of deaths, serious injuries and malfunctions Form FDA 3500A* FDA Within 30 calendar days of becoming aware of an event
  5-day reports for an event designated by FDA or an event that requires remedial action to prevent an unreasonable risk of substantial harm to the public health Form FDA 3500A* FDA Within 5 work days of becoming aware of an event
Importers Reports of deaths and serious injuries Form FDA 3500A* FDA and the manufacturer Within 30 calendar days of becoming aware of an event
  Reports of malfunctions Form FDA 3500A* Manufacturer Within 30 calendar days of becoming aware of an event

*Or electronic equivalent

Table above has been reproduced from FDA Guidance “Mandatory Reporting Requirements: Manufacturers, Importers and Device User Facilities,” last accessed 10/19/2024.

Mandatory Reporting Requirements: Manufacturers, Importers and Device User Facilities, last accessed 10/19/2024 

FDA MedWatch Form 3500A  

FDA MedWatch Form 3500A Supplement – General Instructions for Form 3500A 

 

FDA MEDICAL DEVICE WEBSITES AND ONLINE RESOURCES 

FDA Electronic Submissions Gateway (ESG)  

For assistance with the registration or testing process, contact ESGHelpDesk@fda.hhs.gov

Mandatory Reporting Requirements: Manufacturers, Importers and Device User Facilities 

Options for manufacturers and importers to electronically submit Medical Device Reporting (MDRs): 

  • Web Interface using the eSubmitter application
  • AS2 Gateway-to-Gateway using HL7 ICSR XML

Medical Device Reporting (MDR) - Contact Information for User Facilities and Manufacturers 

FDA Manufacturer and User Facility Device Experience (MAUDE) database 

Reporting Allegations of Regulatory Misconduct 

Allegations of Regulatory Misconduct Form 

CDRH FOIA: How to Get Records from CDRH 

Appendix G: Letters of Non-Repudiation Agreement 

Voluntary Malfunction Summary Reporting Program webpage 

Exemptions, Variances, and Alternative Forms of Adverse Event Reporting for Medical Devices  

Medical Device Reporting, Complaints, and Corrections & Removals Reporting: Laboratory Developed Tests FAQs 

 

FDA PUBLISHED GUIDANCE 

Code of Federal Regulations (CFR) Title 21 Part 803 -- MEDICAL DEVICE REPORTING key terms are defined 

Final Rule on Electronic Medical Device Reporting (eMDR) 

Questions and Answers about eMDR - Electronic Medical Device Reporting - Guidance for Industry, User Facilities and FDA Staff 

Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers; Guidance for Industry and Food and Drug Administration Staff 

Recalls, Corrections and Removals (Devices) 

 

FDA WEBINARS / CDRH LEARN MODULES  

Complaint Files (presentation) 

8/22/2024: In Vitro Diagnostic Products (IVDs) - MDR Requirements, Correction and Removal Reporting Requirements, and Quality System Complaint Requirements 

12/3/2024: Webinar – Registration & Listing Requirements for In Vitro Diagnostic Products (IVDs), Including Laboratory Developed Tests (LDTs)  

Registration and Listing 

Medical Device Reporting (MDR) 

Medical Device Recalls 

Inspections - Global Harmonization 

 

QUESTIONS ABOUT MEDICAL DEVICE REPORTING, including interpretation of MDR policy 

Call: (301) 796-6670  Email: MDRPolicy@fda.hhs.gov 
Or write to:

Food and Drug Administration, Center for Devices and Radiological Health, MDR Reporting Team,  

10903 New Hampshire Avenue, WO Bldg. 66, Room 3217, Silver Spring, MD 20993-0002 

    

DOCUMENT RESOURCES 

Navigating FDA’s LDT Final Rule: Key Terminology Every Clinical Lab Should Know (Today’s Clinical Lab) 

 

ONLINE RESOURCES Coming soon!

 

ADDITIONAL WEBINARS 

Understanding Post-Market Surveillance (PMS) for Medical Devices (eLeaP)  


STAGE 2: Registration & Listing, Labeling, Investigational Device Exemption (IDE)  

FDA WEBSITES AND ONLINE RESOURCES 

FDA Establishment Registration & Device Listing Database 

Labeling: Laboratory Developed Tests FAQs 

Investigational Use: Laboratory Developed Tests FAQs 

 

FDA PUBLISHED GUIDANCE 

Device Registration and Listing 

In Vitro Diagnostic Device Labeling Requirements 

Device Labeling 

Investigational Device Exemption (IDE) | FDA 

Proposed Rule: Microbiology Devices; Reclassification of Antigen, Antibody, and Nucleic Acid-Based Hepatitis B Virus Assay Devices (9/25/2024) 

 

FDA WEBINARS / CDRH LEARN MODULES 

9/24/2024: Labeling Requirements for In Vitro Diagnostic Products (IVD), including LDTs, Under 21 CFR 809.10(b) 

Clinical Studies/Investigational Device Exemption (IDE) 

Humanitarian Use Device (HUD)/Humanitarian Device Exemption (HDE) 

 

DOCUMENT RESOURCES 

Navigating FDA’s LDT Final Rule: Key Terminology Every Clinical Lab Should Know (Today’s Clinical Lab) 

 

ONLINE RESOURCES  Coming soon!

 

ADDITIONAL WEBINARS  Coming Soon!


STAGE 3: Quality System Requirements (QSR), Design Controls, Purchasing Controls, Acceptance Activities, Corrective & Preventative Actions, Records Requirements  

FDA PUBLISHED GUIDANCE 

QS Regulation/Medical Device Current Good Manufacturing Practices (CGMP) 

Medical Device Reporting, Complaints, and Corrections & Removals Reporting: Laboratory Developed Tests FAQs 

 

WEBINARS / CDRH LEARN MODULES 

Overview of the Quality System (Start here!) 

Quality Management System Regulation (8/30/24) 

Exports and Imports 

General Policy 

 

FDA RECOGNIZED STANDARDS (not an exhaustive list) 

CLSI$ not a complete list of available resources

ISO Documents$ not a complete list of available resources

 

OTHER WEBINARS 

CLSI Quality Management Systems webinars (multiple:CLIS) 

ISO15189WR Medical Laboratories—Requirements for Quality and Competence: Changes from the Third Edition (2012) to the Fourth Edition (2022) Webinar 

QMSR Masterclass  

Unpacking FDA Guidance: Quality System Considerations and Content of Premarket Submissions (MedCrypt)

QSR to QMSR: The Rewrite of 21 CFR Part 820 & Key Considerations for FDA Compliance (Greenlight Guru)   

 

DOCUMENT RESOURCES 

Navigating FDA’s LDT Final Rule: Key Terminology Every Clinical Lab Should Know (Today’s Clinical Lab) 

 

ONLINE RESOURCES 

CLSI$ not a complete list of available resources

 

ADDITIONAL WEBINARS  Coming soon!


STAGE 4: Premarket Approval (PMA) Required for High-risk In Vitro Diagnostics (IVDs)  

FDA WEBSITES AND ONLINE RESOURCES 

FDA Device Classification Database 

Definitions and General Oversight: Laboratory Developed Tests FAQs 

Specific Test Categories or Technologies: Laboratory Developed Tests FAQs 

Phaseout Policy and Enforcement Discretion Policies: Laboratory Developed Tests FAQs 

Premarket Review: Laboratory Developed Tests FAQs 

Resources and Interactions with FDA: Laboratory Developed Tests FAQs 

 

FDA PUBLISHED GUIDANCE 

Premarket Submissions: Selecting and Preparing the Correct Submission | FDA 

The Special 510(k) Program 

Deciding When to Submit a 510(k) for a Change to an Existing Device 

8/22/2024 Draft Guidance: Predetermined Change Control Plans for Medical Devices 

Proposed Rule: Microbiology Devices; Reclassification of Antigen, Antibody, and Nucleic Acid-Based Hepatitis B Virus Assay Devices (9/25/2024) 

 

FDA WEBINARS / CDRH LEARN MODULES 

Risk Basics for Medical Devices  

Application of Risk Management Principles for Medical Devices  

6/11/2024: Enforcement Policies for Certain In Vitro Diagnostic Devices - Draft Guidances Slides Transcript 

8/18/2024: In Vitro Diagnostic Product (IVD): Classification Slides Transcript 

Classification 

Premarket Approval Application (PMA) 

Premarket Notification (510k) 

Q-Submissions 

Cross-Cutting Premarket Policy 

De Novo 

 

DOCUMENT RESOURCES 

Navigating FDA’s LDT Final Rule: Key Terminology Every Clinical Lab Should Know (Today’s Clinical Lab) 

 

ONLINE RESOURCES Coming soon!

 

ADDITIONAL WEBINARS 

LDT vs IVD: Adapting to the New FDA Regulations (MCRA)  

Understanding the FDA Pre-Market Approval (PMA) Process for Medical Devices (eLeap)  

10 Steps to Preparing Your 510(k) Submission (and How to Avoid the Common Pitfalls) (Greenlight Guru)  

Unpacking FDA Guidance: Quality System Considerations and Content of Premarket Submissions (MedCrypt)  


New York State DOH LDT 3rd Party Review Program

Only laboratories that hold a New York State clinical laboratory permit are authorized to perform testing on specimens originating from New York. Review of LDT begins after the clinical laboratory permit application has been submitted. LDT review is not offered as a stand-alone service.

NYSDOH RESOURCES 

Obtain a NYS Clinical Laboratory Permit 

Certificate of Qualification & Laboratory Director Requirements 

Application Procedures for Test Approval 

Tiered Evaluation of Laboratory Developed Tests Policy

DOCUMENT RESOURCES 

Sept 2024: NYS Clinical Laboratory Association Newsletter – FDA’s Final Rule Regulating LDTs (Jane Pine Wood) 


FDA CDER Medical Device Digital Health Resources 

FDA MEDICAL DEVICE WEBSITES AND ONLINE RESOURCES 

3/13/2024: Draft Guidance: Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the FD&C Act  

09/27/2023: Final Guidance: Content of Premarket Submissions for Management of Cybersecurity in Medical Devices  

FDA Digital Health and Artificial Intelligence Glossary – Educational Resource 

Playbook for Threat Modeling Medical Devices 

1/02/2023: Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions  

Next Steps Toward Managing Legacy Medical Device Cybersecurity Risks (FDA via contract with MITRE) 

Software as a Medical Device (SaMD)  

Artificial Intelligence and Machine Learning in Software as a Medical Device

Listing of Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices  

Good Machine Learning Practice for Medical Device Development: Guiding Principles  

Predetermined Change Control Plans for Machine Learning-Enabled Medical Devices: Guiding Principles  

Guidances with Digital Health Content  

Cybersecurity in Medical Devices Frequently Asked Questions (FAQs)  

Your Clinical Decision Support Software: Is It a Medical Device?  

 

FDA WEBINARS / CDRH LEARN MODULES 

Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act: Final Guidance Slides Transcript 

Clinical Decision Support Software, Final Guidance Transcript 

Content of Premarket Submissions for Device Software Functions, Final Guidance Slides Transcript 

Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions - Final Guidance Slides Transcript 

Design Considerations and Premarket Submission Recommendations for Interoperable Medical Devices Final Guidance Slides Transcript 

Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions Slides Transcript 

Postmarket Management of Cybersecurity in Medical Devices Final Guidance Slides Transcript 

4/30/2024: Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the FD&C Act, Draft Guidance Slides Transcript 


Molecular Testing Validation Resources

FDA MEDICAL DEVICE WEBSITES AND ONLINE RESOURCES 

Definitions and General Oversight: Laboratory Developed Tests FAQs 

Specific Test Categories or Technologies: Laboratory Developed Tests FAQs 

Phaseout Policy and Enforcement Discretion Policies: Laboratory Developed Tests FAQs 

Premarket Review: Laboratory Developed Tests FAQs 

Resources and Interactions with FDA: Laboratory Developed Tests FAQs 

Labeling: Laboratory Developed Tests FAQs 

Medical Device Reporting, Complaints, and Corrections & Removals Reporting: Laboratory Developed Tests FAQs 

Investigational Use: Laboratory Developed Tests FAQs 

FDA PUBLISHED GUIDANCE 

Proposed Rule: Microbiology Devices; Reclassification of Antigen, Antibody, and Nucleic Acid-Based Hepatitis B Virus Assay Devices (9/25/2024) 

FDA WEBINARS / CDRH LEARN MODULES 

See STAGE 3 section above - FDA Webinars / CDRH Learn Modules about QSR / QMSR  

Standards 

 

FDA RECOGNIZED STANDARDS FOR MOLECULAR TESTING (not an exhaustive list) 

CLSI$ not a complete list of available resources

ISO$

 

DOCUMENT RESOURCES 

CLSI LDT Response Documents  

Navigating FDA’s LDT Final Rule: Key Terminology Every Clinical Lab Should Know (Today’s Clinical Lab) 

 

ONLINE RESOURCES  Coming soon!

ADDITIONAL WEBINARS  Coming soon!

CLSI$ not a complete list of available resources

Assorted sponsors 

 

Disclaimer: With the exception of resources labeled above as having been generated by AMP, links will take you to external websites. Resources above are the sole responsibility of the entity providing them. AMP does not endorse any commercial product or service. AMP makes no warranty, express or implied, regarding any commercial product or service, and hereby disclaims, the accuracy, completeness, timeliness or merchantability or fitness for a particular purpose of the content and associated materials presented above. AMP shall not be liable for any damages, including direct, indirect, special, incidental, or consequential or any other type of damages arising out of or related to the use of the information contained on this page or associated materials.

Corporate Partners